Scilex Holding Company (NASDAQ:SCLX) Financings
Financings
| Raise | Date |
|---|---|
| Strategic investment of newly issued shares of common stock Announced: US$100M · US$10 a share Buyers: iHolding Group LLP ($100,000,000 of newly issued shares of Semnur common stock) Use of proceeds: Pipeline advancement incl. Phase 3 SEMDEXA (SP-102), commercialization, acquisitions and partnerships, working capital, IP, general corporate purposes | Jul 7, 2026 |
| Strategic investment of common stock Announced: US$100M · US$15 a share Buyers: iHolding Group LLP ($100,000,000 of newly issued shares of common stock at $15.00 per share, approximately 6,666,667 shares) Use of proceeds: Strategic growth, healthcare and medtech initiatives, product development, acquisitions and partnerships, working capital, IP and general corporate purposes | Jul 6, 2026 |
| Warrant exercise of shares of common stock on exercise of existing warrants Closed: US$20.3M raised · US$22.51 a share · Warrants at US$29 for 60 months · Rodman & Renshaw LLC +1 Dealers: Rodman & Renshaw LLC (co-lead), StockBlock Securities LLC (co-lead) Use of proceeds: Working capital and general corporate purposes | Nov 25, 2025 |
| Registered direct offering of common stock, pre-funded warrants and accompanying common warrants Announced: about US$17M · US$0.59 a share · ½ warrant at US$0.649 Use of proceeds: Working capital and general corporate purposes, including commercialization, R&D, clinical trials, acquisitions and debt repayment | Dec 12, 2024 |
| Warrant exercise of outstanding warrants issued in March 2024 Announced: about US$1M · US$0.59 a share | Dec 12, 2024 |